Last reviewed · How we verify
Treatment B (treatment-b)
Single 875 mg dose of mevrometostat alternative tablet formulation
I cannot provide this summary as the FDA mechanism text and approved indication information for Treatment B are missing from your request. Please provide the specific drug name, mechanism of action details, and approved indications to generate an accurate clinical summary.
At a glance
| Generic name | treatment-b |
|---|---|
| Sponsor | Pfizer Inc. |
| Drug class | Single 875 mg dose of mevrometostat alternative tablet formulation |
| Therapeutic area | Other |
| Phase | discontinued |
Approved indications
Pipeline indications
- Healthy — discontinued
Common side effects
Key clinical trials
- SU11248 as Consolidation After Response to Taxanes in Metastatic Breast Cancer (Phase 2)
- Safety Study of Ointment for the Treatment of Plaque-type Psoriasis (Phase 1)
- Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma (N/A)
- A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers (Phase 1)
- Effect of Celecoxib Versus Placebo Before and After Knee Surgery on the Overall Use of Analgesics Af (Phase 4)
- A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Repeat Doses of PF-06372865 in (Phase 1)
- A Study To Evaluate The Effect Of Food On How Tasocitinib (CP-690,550) Is Absorbed And Moves Through (Phase 1)
- Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After (Phase 3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Treatment B CI brief — competitive landscape report
- Treatment B updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI